Roche Holding AG Said to Return Diabetes Drug Rights to Ipsen Because of Side Effects

February 1, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Bloomberg -- Roche Holding AG returned rights to the experimental diabetes drug taspoglutide to developer Ipsen SA after patients dropped out of trials because of side effects, according to two people with knowledge of the matter.

Twitter
LinkedIn
Facebook
Email
Print

Alliances

Ipsen Biopharmaceuticals, Inc.